CorMedix CRMD Deferred Tax Assets Capitalized Licensing Fees
Deferred Tax Assets Capitalized Licensing Fees at other companies
Other financials
Where this comes from
Reported directly by CorMedix in its filing.
Tagged under the XBRL concept crmd:DeferredTaxAssetsCapitalizedLicensingFees.
The official record: CorMedix’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about CorMedix's deferred tax assets capitalized licensing fees.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CorMedix's deferred tax assets capitalized licensing fees?
- CorMedix (CRMD) reported deferred tax assets capitalized licensing fees of $31K in Q4 2025.
- How has CorMedix's deferred tax assets capitalized licensing fees changed year-over-year?
- CorMedix's deferred tax assets capitalized licensing fees decreased by 64.0% year-over-year, from $86K to $31K.
- What is the long-term trend for CorMedix's deferred tax assets capitalized licensing fees?
- Over 5 years (2020 to 2025), CorMedix's deferred tax assets capitalized licensing fees has grown at a -44.7% compound annual growth rate (CAGR), from $600K to $31K.
- What does deferred tax assets capitalized licensing fees mean?
- This represents the tax benefit derived from the capitalization and amortization of licensing fees for tax reporting purposes. It reflects future tax savings that the company expects to realize as these costs are deducted over time. This asset highlights the tax-shielding potential of the company's intellectual property investments.